Zafgen Inc. (NASDAQ:ZFGN)’s share price was down 1.4% during mid-day trading on Wednesday . The company traded as low as $6.21 and last traded at $6.25, with a volume of 235,899 shares. The stock had previously closed at $6.34.

A number of brokerages have recently commented on ZFGN. Royal Bank Of Canada lowered their price target on shares of Zafgen from $21.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, March 10th. Canaccord Genuity downgraded shares of Zafgen from a “buy” rating to a “hold” rating and lowered their price target for the stock from $30.00 to $7.00 in a report on Thursday, March 10th. FBR & Co reiterated a “buy” rating and set a $20.00 price target on shares of Zafgen in a report on Friday, March 11th. Leerink Swann reiterated a “market perform” rating and set a $6.00 price target on shares of Zafgen in a report on Thursday, March 17th. Finally, Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Thursday, May 12th. Four investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $11.94.

The company’s market capitalization is $170.45 million. The stock’s 50 day moving average price is $6.45 and its 200-day moving average price is $6.58.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.09. During the same period last year, the company posted ($0.53) earnings per share. Analysts anticipate that Zafgen Inc. will post ($2.81) EPS for the current year.

An institutional investor recently bought a new position in Zafgen stock. Oxford Asset Management purchased a new stake in shares of Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned 0.87% of Zafgen as of its most recent filing with the SEC.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.